港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

湖南麥濟生物技術股份有限公司（臨時代碼）

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

資料載入中...

總覽公司新聞公告

康哲藥業押注，麥濟生物衝刺IPO，這下一款“四周一次”過敏藥唱了主角

医药研究社

麥濟生物衝擊港股IPO：核心在研產品賽道擁擠，曾被判專利侵權三生國健

【新股消息 | 麥濟生物遞表港交所目前並無任何已獲批准或處於商業階段的產品】智通財經APP獲悉，據港交所7月14日披露

48歲博士帶隊、康哲藥業押注，麥濟生物估值26億元衝刺港交所

據港交所文件：湖南麥濟生物技術股份有限公司 - B向港交所提交上市申請書。

康哲藥業將聯手麥濟生物共同推動MG-K10人源化單抗注射液於中國市場上市

康哲藥業與麥濟生物簽署MG-K10人源化單抗注射液合作協議

康哲藥業與麥濟生物就1類新藥抗IL-4Rα人源化單抗注射液MG-K10簽訂合作協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91209/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91209","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","market":"HK","secType":"STK","nameCN":"湖南麥濟生物技術股份有限公司（臨時代碼）","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"07-18 11:30:36","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1752811200000},"marketStatusCode":2,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1752802200000,1752811200000],[1752814800000,1752825600000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91209\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552122878","title":"康哲藥業押注，麥濟生物衝刺IPO，這下一款“四周一次”過敏藥唱了主角","url":"https://stock-news.laohu8.com/highlight/detail?id=2552122878","media":"医药研究社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552122878?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 20:15","pubTimestamp":1752668154,"startTime":"0","endTime":"0","summary":"业绩方面，麦济生物没有太多可说的内容。尤其在麦济生物冲刺IPO这一节点，上述产品很有可能成为资本市场的“敲门砖”。另外，麦济生物招股书透露，公司计划于2025年下半年结束MG-K10治疗成人特应性皮炎III期临床试验，并就该适应症向国家药监局提交BLA申请。结语当前麦济生物等创新药企扎堆IPO，其实也是在强化“创新药的故事从来不止于实验室”这一事实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716202546a6ad80a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716202546a6ad80a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","BK1593","91209","SG9999015952.SGD","SG9999004220.SGD","BK1191","IE00BGHQDM52.EUR","SG9999015986.USD","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","LU2488822045.USD","SG9999015945.SGD","SG9999015978.USD","IE00BYV24P56.USD","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2552171035","title":"麥濟生物衝擊港股IPO：核心在研產品賽道擁擠，曾被判專利侵權三生國健","url":"https://stock-news.laohu8.com/highlight/detail?id=2552171035","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552171035?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 16:26","pubTimestamp":1752654414,"startTime":"0","endTime":"0","summary":"不过，值得注意的是，麦济生物曾就IL-4Rα相关专利与科创板上市公司三生国健有过一起诉讼纠纷。此外，麦济公司并未提供涉案专利申请技术研发的任何实验数据。不过，麦济生物并未在MG-K10产品的核心专利中列入上述侵权的专利。2016年至2025年，麦济生物完成了多轮融资和股权转让。张成海及麦康克将被视为一组控股股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1752654196920222185","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["YANG","HSTECH","HSCEI","BK4614","91209"],"gpt_icon":1},{"id":"2551415698","title":"【新股消息 | 麥濟生物遞表港交所 目前並無任何已獲批准或處於商業階段的產品】智通財經APP獲悉，據港交所7月14日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2551415698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551415698?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 14:07","pubTimestamp":1752559654,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03908","BK1501","SG9999002828.SGD","91209","HEXmain","BK0276","BK1564","601995","BK1147","BK1516"],"gpt_icon":0},{"id":"2551615682","title":"48歲博士帶隊、康哲藥業押注，麥濟生物估值26億元衝刺港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2551615682","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551615682?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 13:49","pubTimestamp":1752558560,"startTime":"0","endTime":"0","summary":"2023年、2024年及2025年一季度，麦济生物收入分别为872.2万元、2.4万元、0元，期内亏损分别为2.53亿元、1.78亿元、2726.7万元。2025年7月11日，麦济生物完成递表前最后一轮融资，此次融资规模为2.6亿元。完成本轮融资后，公司的投后估值攀升至26.4亿元。张成海及麦康克被视为一组控股股东。资料显示，张成海，48岁，于2016年9月创立麦济生物并担任唯一董事，并自2016年12月起担任董事长兼首席执行官。张成海于2025年7月调任为执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071513495897a69c83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071513495897a69c83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BGHQDM52.EUR","BK1593","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999015952.SGD","SG9999015978.USD","SG9999004220.SGD","LU2488822045.USD","SG9999015986.USD","BK1191","91209","00867","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2551184838","title":"據港交所文件：湖南麥濟生物技術股份有限公司 - B向港交所提交上市申請書。","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184838","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551184838?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 21:33","pubTimestamp":1752500031,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["91209","HEXmain"],"gpt_icon":0},{"id":"2506359631","title":"康哲藥業將聯手麥濟生物共同推動MG-K10人源化單抗注射液於中國市場上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2506359631","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506359631?lang=zh_tw&edition=fundamental","pubTime":"2025-01-26 19:36","pubTimestamp":1737891399,"startTime":"0","endTime":"0","summary":"发稿人张敏本报讯（记者李雯珊）1月24日，康哲药业控股有限公司（以下简称“康哲药业”）发布公告称，通过其附属公司与湖南麦济生物技术股份有限公司（“麦济生物”）及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。根据协议，康哲药业获得MG-K10在中国及新加坡的共同开发权及独家商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501263308459833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","YINN","MG","SG9999015945.SGD","BK1593","BK1191","00867","SG9999015978.USD","IE00BMCWC346.EUR","SG9999015952.SGD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4585","IE00BYV24P56.USD","91209","SG9999015986.USD","IE0031619046.USD","BK4123","BK4588","IE00B19Z4B17.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2505576038","title":"康哲藥業與麥濟生物簽署MG-K10人源化單抗注射液合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2505576038","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505576038?lang=zh_tw&edition=fundamental","pubTime":"2025-01-24 21:11","pubTimestamp":1737724279,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/JMMRCR7B05568V7Z.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/JMMRCR7B05568V7Z.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["91209"],"gpt_icon":0},{"id":"2505526188","title":"康哲藥業與麥濟生物就1類新藥抗IL-4Rα人源化單抗注射液MG-K10簽訂合作協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2505526188","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505526188?lang=zh_tw&edition=fundamental","pubTime":"2025-01-24 20:50","pubTimestamp":1737723038,"startTime":"0","endTime":"0","summary":"格隆汇1月24日丨康哲药业公告，于2025年1月24日，集团通过公司附属公司与湖南麦济生物技术股份有限公司及其附属公司就1类新药抗IL-4Rα人源化单抗注射液MG-K10签订合作协议。MG-K10的AD、哮喘和结节性痒疹均已进入中国III期临床试验阶段。MG-K10的Fc突变可有效延长半衰期，降低给药频率，有望成为国内首个上市的长效抗IL-4Rα单抗。IL-4Rα被认为是治疗2型炎症性疾病的关键靶点，抗IL-4Rα单抗则是目前2型炎症性疾病领域最畅销的生物制剂之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501242051279871ec9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501242051279871ec9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91209","IE00BMCWC346.EUR","LU2488822045.USD","SG9999015986.USD","BK1593","00867","SG9999004220.SGD","SG9999015952.SGD","SG9999015978.USD","SG9999015945.SGD","IE00BYV24P56.USD","BK1191"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91209\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91209\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91209\",market:\"HK\",delay:false,,,undefined,":{}}}